[HTML] thieme-connect.com

[HTML][HTML] Non–Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease

S Al Said, M Ellscheid, ET Beltsios, N Frey - Hämostaseologie, 2022 - thieme-connect.com
The prevention of atherothrombotic events is the primary goal in the treatment of patients
with arteriosclerotic disorders. Despite recent improvements in the management of coronary …
被引用次数：2 相关文章

Non–Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease

S Al Said, M Ellscheid, ET Beltsios, N Frey - Hämostaseologie, 2022 - thieme-connect.com
The prevention of atherothrombotic events is the primary goal in the treatment of patients
with arteriosclerotic disorders. Despite recent improvements in the management of coronary …

Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease

S Al Said, M Ellscheid, ET Beltsios… - …, 2022 - pubmed.ncbi.nlm.nih.gov
The prevention of atherothrombotic events is the primary goal in the treatment of patients
with arteriosclerotic disorders. Despite recent improvements in the management of coronary …

Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease.

S Al Said, M Ellscheid, ET Beltsios, N Frey - Hamostaseologie, 2021 - europepmc.org
The prevention of atherothrombotic events is the primary goal in the treatment of patients
with arteriosclerotic disorders. Despite recent improvements in the management of coronary …

Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease

S Al Said, M Ellscheid, ET Beltsios, N Frey - 2022 - ir.lib.uth.gr
The prevention of atherothrombotic events is the primary goal in the treatment of patients
with arteriosclerotic disorders. Despite recent improvements in the management of coronary …